Comparison: other vs 'Sorafenib'			
Treatment	(Random Effects Model)	HR	95%-Cl
Atezolizumab+Bevacizumab Atezolizumab+Cabozantinib Camrelizumab+Apatinib Durvalumab Durvalumab+Tremelimumab Lenvatinib Nivolumab Pembrolizumab+Lenvatinib Placebo Tislelizumab		1.18 (0 0.71 (0 0.82 (0 0.74 (0 1.03 (0 0.95 (0 0.89 (0 1.32 (0).68; 1.63]).78; 1.79]).37; 1.36]).64; 1.05]).57; 0.96]).47; 2.27]).47; 2.27]).47; 2.27]).47; 2.27]).47; 2.27]).47; 2.20]).47; 2.04]).86; 2.00] 0.55; 1.11]

Supplementary Figure 27. Forest plots showing the overall survival in subpopulation with non-viral HCC considering sorafenib as reference